Apremilast: Phase III data

Top-line data from the double-blind, international Phase III PALACE-3 trial in about 500 patients showed that twice-daily 20 and 30 mg oral apremilast each met the primary endpoint of ACR20 response rate at week 16 vs. placebo. Celgene said patients in the apremilast arms maintained the ACR20 response through week 24. PALACE-3 enrolled patients with active psoriatic arthritis who had failed oral DMARDs, and/or an anti- tumor necrosis factor (TNF) agent. PALACE-3 is the third of 3 Phase III trials of apremilast in psoriatic arthritis. Apremilast met the primary endpoint of ACR20 response rate in PALACE-1 and PALACE-2. ...